A Phase 3 interventional study of Zeleciment Rostudirsen (DYNE-251) and Placebo in Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne and Muscular Dystrophy (DMD), sponsored by Dyne Therapeutics. Recruiting at 1 site in United States. Open to male participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Dyne Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 34th largest by planned enrollment of the 172 interventional ones that give a count, is one of 9 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 50 of the 59 other live ones, and was the 229th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 18 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 161 that completed or were terminated, 78 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
Dyne Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Dyne Therapeutics has 2 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
18 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05016908Massachusetts General HospitalExtracellular RNA Biomarkers of Duchenne Muscular Dystrophy | 2026-12 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
The study consists of three periods: a Screening period (up to 6 weeks), a Placebo-Controlled Period (72 weeks) and an open-label Long-Term Extension Period (96 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion or exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive zeleciment rostudirsen, once every 4 weeks (Q4W) for up to 72 weeks.
Drug: Zeleciment Rostudirsen (DYNE-251)
Participants will be randomized to receive placebo, Q4W for up to 72 weeks.
Drug: Placebo
All participants who complete the Placebo-Controlled Period of the study will receive zeleciment rostudirsen administered Q4W for up to 96 weeks.
Drug: Zeleciment Rostudirsen (DYNE-251)
Administered by IV infusion
Administered by IV infusion
Rise From Floor (RFF) velocity
Time frame: Baseline, Week 73
RFF (Rise From Floor) velocity
Time frame: Baseline, up to Week 169
Stride Velocity 95th Percentile (SV95C)
Time frame: Baseline, Week 73, up to Week 169
North Star Ambulatory Assessment (NSAA) Total Score
Time frame: Baseline, Week 73, up to Week 169
10-Meter Walk/Run (10MWR) Velocity
Time frame: Baseline, Week 73, up to Week 169
4-Stair Climb (4SC) velocity
Time frame: Baseline, Week 73, up to Week 169
Functional Composite score
Time frame: Baseline, Week 73, up to Week 169
Forced Vital Capacity (FVC)
Time frame: Baseline, Week 73, up to Week 169
Patient Global Impression of Severity (PGI-S)
Time frame: Baseline, Week 73, up to Week 169
Outcome of Patient Global Impression of Change (PGI-C)
Time frame: Week 73, up to Week 169
Blood Creatine Kinase (CK) levels
Time frame: Baseline, Week 73, up to Week 169
Incidence of participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through study completion, up to Week 173
Maximum Observed Plasma Drug Concentration of DYNE-251 (Cmax)
Time frame: Through study completion, up to Week 169
Time to Maximum Observed Plasma Drug Concentration of DYNE-251 (tmax)
Time frame: Through study completion, up to Week 169
Area Under the Plasma Drug Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration of DYNE-251 in Plasma (AUC-tlast)
Time frame: Through study completion, up to Week 169
Area Under the Plasma Drug Concentration Versus Time Curve From Time 0 (Dosing) Extrapolated to Time Infinity of DYNE-251 (AUC∞)
Time frame: Through study completion, up to Week 169
Apparent Terminal Phase Elimination Rate Constant of DYNE-251 in Plasma (λz)
Time frame: Through study completion, up to Week 169
Apparent Terminal Elimination Half-Life of DYNE-251 in Plasma (t½)
Time frame: Through study completion, up to Week 169
Total Body Clearance (CL) of DYNE-251
Time frame: Through study completion, up to Week 169
Volume of Distribution at the Terminal Phase of DYNE-251 in Plasma (Vz)
Time frame: Through study completion, up to Week 169
Volume of Distribution at Steady State of DYNE-251 in Plasma (Vss)
Time frame: Through study completion, up to Week 169
Incidence of Participants With Antidrug Antibodies (ADAs)
Time frame: Through study completion, up to Week 169
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2030, 54 months later.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 54 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Dyne Therapeutics